Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.

MLA

Yonal-Hindilerden, Ipek, et al. “Prognostic Significance of ASXL1, JAK2V617F Mutations and JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms.” Journal of Blood Medicine, vol. 6, June 2015, pp. 157–75. EBSCOhost, https://doi.org/10.2147/JBM.S78826.

APA

Yonal-Hindilerden, I., Daglar-Aday, A., Akadam-Teker, B., Yilmaz, C., Nalcaci, M., Yavuz, A. S., & Sargin, D. (2015). Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. Journal of Blood Medicine, 6, 157–175. https://doi.org/10.2147/JBM.S78826

Chicago

Yonal-Hindilerden, Ipek, Aynur Daglar-Aday, Basak Akadam-Teker, Ceylan Yilmaz, Meliha Nalcaci, Akif Selim Yavuz, and Deniz Sargin. 2015. “Prognostic Significance of ASXL1, JAK2V617F Mutations and JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms.” Journal of Blood Medicine 6 (June): 157–75. doi:10.2147/JBM.S78826.